ImmuCell Buries Re-Tain, Then Turns the Building Into a Freeze Dryer
Q3 sales up 46%, gross margin back to 44.2%, and the pipeline question that hung over six straight calls finally got answered — negatively, and profitably
ICCC · Earnings Call · 2026-11-13
The Question That Finally Got an Answer
For six quarters running, ImmuCell's calls carried the same unresolved line item: Re-Tain. On the August call, Olivier te Boekhorst was still deferring — “we're, in fact, awaiting the results of the investigational study by Michigan State, which we expect to be completed September, October time frame before we make any further decisions on our Re-Tain product” — P. F. Te Boekhorst, Chief Executive Officer · 2026-08-14. This quarter the decision landed, and it landed negative: “The trial that we completed this quarter effectively changed nothing in the sense that we did not find new use cases for the product, so Re-Tain activities remain paused.” — Olivier te Boekhorst, Executive (likely CEO) · 2026-11-13 No further development spend. A minor licensing deal with an aquaculture company for certain marine species rights. That's it.
What makes this more than an obituary is the physical asset. The building that used to make nisin for Re-Tain — a building "just down the road" from the main plant — is now the site of a new freeze dryer that Tim Fiori says “will produce more than all four of those combined” — Timothy Fiori, Executive (likely CFO or similar financial role) · 2026-11-13 the company's existing four units. The failed pipeline has been converted into capacity. That is a cleaner strategic reset than most micro-caps manage, and it is why this quarter reads as a different company than the one that took the call a year ago, when a private investor jabbed at management for walking away from an expansion: “what has changed? It went from an expansion of capacity. We even committed capital, and now we're uncommitted to that expansion.” — Frank Gasca, Private Investor · 2025-11-14 As of September 30, $1.7 million of an $8 million plan is actually spent and a lot of the key equipment is ordered.
The company is now, in the CEO's words, focused exclusively on First Defense — and on protecting the calf, not the cow.
Volume Is the Margin
Gross margin went from 33.9% in Q2 to 44.2% in Q3, and Frank Gasker asked the only question that mattered: “What specifically changed between Q2 and Q3 to restore gross margins to 44%? Are those improvements sustainable?” — Frank Gasker, Analyst · 2026-11-13 The answer was output, plus a small August price increase. Average monthly production ran ~435,000 manufacturing units in 2026, up 14% year-over-year and a long way from the 252,000 of 2023, when contamination events were shredding the yield. Because the manufacturing cost base is relatively fixed, output is the margin in this business.
Which is why the *reported* number understates the quarter. The Re-Tain cost shift is now sitting inside cost of goods sold:
The shift of Re-Tain product development expenses to cost of goods sold due to the decision to repurpose the Re-Tain facility and equipment to First Defense resulted in approximately $400,000 of expenses being shifted to cost of goods sold, which reduces the Q3 stated gross margin by 480 basis points.
That is roughly a five-point anchor dragging on a 44.2% print — dollar-stable, percentage-shrinking as volume grows. Strip it out and the underlying run rate is north of 49%. Gross margin went from a 9% trough in 2023Q1 to 44.2% in the just-reported quarter — a recovery the filed data won't show until next quarter, since the latest fundamentals snapshot still reflects Q2's 33.9%.
The next leg is hardware, not just discipline. The freeze dryer project is a bottleneck-breaker: drying is the constraint, and the freeze-drying phase is due in the first half of 2027 with liquids processing by year-end 2027. Management's claim — “we believe we have enough capacity and further improvement potential to meet demand” — Olivier te Boekhorst, Executive (likely CEO) · 2026-11-13 until then — is a bet on continued manufacturing yield gains rather than a promise of headroom.
A $15 Shield for a $2,000 Calf
The demand side is the most interesting part of this story, because it is genuinely structural rather than cyclical. Calf values have risen fivefold since 2021 — “Whether it's a calf born in a traditional beef herd or one originating on a dairy, their value has risen fivefold since 2021” — Olivier te Boekhorst, Executive (likely CEO) · 2026-11-13 — and the CEO's arithmetic is that protecting a calf worth more than $2,000 with a $15 product makes a lot of sense today. Tight cattle supplies are expected to keep that true through 2027 and 2028. In a market where the asset being insured quintupled while the insurance premium didn't, the sales conversation gets easier every year.
It's being monetized through feet on the ground. The commercial team went from nine to 13 people since last November; new customers contributed 46% of net growth in Q3 and existing customers 54% — a healthy split that suggests both share capture and wallet expansion. commercial activity is the operative phrase, and it's the kind of thing that compounds for a company with roughly 34% of U.S. bovine-scours biological spend.
The genuinely new wedge is Functional Feed, aimed at calf ranchers handling more than four million calves. It uses the same hyper-immunized colostrum but a cheaper drying technology and a much lower price per dose, so ranchers can treat every incoming animal rather than guess which ones got Tri-Shield at birth. Management says it delivered 50% lower pre-weaning removal rates and met full-year targets already. Not reported as a segment, but strategically it's the difference between selling to dairy producers and selling to the industrial-scale side of the beef-on-dairy complex.
What's Left to Prove
The bear case hasn't vanished; it has moved down the supply chain. colostrum sourcing is now the acknowledged pinch point — “It is a competitive market for colostrum sourcing, and we are seeing an increase in prices.” — Olivier te Boekhorst, Executive (likely CEO) · 2026-11-13 Higher input costs meeting a fixed-cost manufacturing base is precisely the mix that can undo a yield-driven margin story, and the company's own keyword set shows product cost losing momentum this quarter even as revenue momentum builds.
Second, the international line deserves skepticism. Sales outside the U.S. grew 573% to $1.1 million, but management attributes the bulk to Canada and to clearing of 2025 back orders. ImmuCell has a documented habit of one-time compares: on the August 2025 call the CFO noted “the backlog at the end of March was -- at March 31, 2025, was $4 million. And we have worked through that backlog during the second quarter” — Timothy C. Fiori, Chief Financial Officer · 2025-08-15. The Q3 2026 domestic number (up 29.2%) is the cleaner read.
Balance sheet risk, at least, is receding. The company finished the quarter with $7.9 million of cash and roughly $3 million of finished-goods inventory heading into its beef-calving peak, upsized its credit line from $1 million to $3 million over three years, and terminated an at-the-market facility unused since May 2025. Effective net cash sat at roughly negative $1 million in the last filed quarter; with the $2 million legal settlement banked and no equity drawn, that line should be close to flat or positive now. Capital expenditure is ramping for the first time since 2017, funded from operations rather than dilution.
And then there's the tape. ImmuCell trades near $10.75, within 9.5% of its February 2021 high of $11.88, and has done essentially nothing for 90 days. At 3.0x price to revenue, the market has already granted the recovery. Q3 beat; the stock is flat. That is the tension of this report: the operating story is now demonstrably better than it has been in three years, and the price already says so. What's left is the boring part — colostrum costs, a freeze dryer in 2027, and a Q4 that has to hold margin without the backlog tailwind. For a company that spent two years answering the same pipeline question, showing up with a working plant and a $15 product on a $2,000 animal is progress worth taking seriously.